Skip to main content

Table 2 Patient, donor, and transplant characteristics

From: Early myeloid-derived suppressor cells (HLA-DR/lowCD33+CD16) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT

 

MDSCs low

MDSCs high

p

Number

47

53

 

Patient age, median (range)

32 (5–62)

30 (2–53)

NS

Patient sex, male (%)

30 (63.8%)

29 (54.7%)

NS

Diagnosis

  

NS

 AML, n (%)

21 (44.7%)

18 (34.0%)

 

 ALL, n (%)

13 (27.7%)

16 (30.2%)

 

 MDS, n (%)

3 (6.4%)

5 (9.4%)

 

 SAA, n (%)

6 (12.8%)

8 (15.1%)

 

 Lymphoma or myeloma, n (%)

4 (8.5%)

6 (11.3%)

 

Disease Risk Index (DRI) overall

  

NS

 Low, n (%)

3 (6.7%)

2 (4.4%)

 

 Intermediate, n (%)

5 (12.2%)

7 (15.5%)

 

 High, n (%)

29 (70.7%)

32 (63.4%)

 

 Very high, n (%)

4 (9.8%)

4 (8.9%)

 

Donor Type

 MSD, n (%)

13 (27.7%)

11 (20.8%)

NS

 Haplo, n (%)

34 (72.3%)

42 (79.2%)

NS

  1 Locus, n (%)

1 (2.1%)

0 (0%)

 

  2 Locus, n (%)

2 (4.3%)

3 (5.7%)

 

  3 Locus, n (%)

31 (65.9%)

39 (73.6%)

 

Engraftment

 WBC + days, median (range)

14 (10–22)

12 (10–24)

 

 PLT + days, median (range)

14 (7–32)

13.5 (8–63)

 

Cells in allograft

 CD34+ (× 106/kg), median (range)

1.92 (0.62–5.85)

3.14 (0.64–6.85)

0.002

 CD3+ T (× 108/kg), median (range)

2.31 (0.61–3.79)

2.63 (0.82–5.79)

NS

 CD4+ (× 108/kg), median (range)

1.21 (0.32–2.12)

1.49 (0.43–3.42)

NS

 CD8+ (× 108/kg), median (range)

0.72 (0.15–1.87)

0.92 (0.31–2.29)

NS

  1. AML acute myeloid leukemia, ALL acute lymphoid leukemia, MDS myelodysplastic syndromes, SAA severe aplastic anemia, NS not significant